SCHEMBL25752565

SCHEMBL25752565

Cn1cc(N)c2c(=O)n(C3CC3)ccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.34
ALDH1A1 P00352 4/20 0.33
GRM1 Q13255 2/20 0.33
BRD4 O60885 1/20 0.32
BRD2 P25440 1/20 0.32
BRD3 Q15059 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.31
PRKCG P05129 2/20 0.31
PRKCB P05771 2/20 0.31
PRKCA P17252 2/20 0.31
PRKCH P24723 2/20 0.31
PRKCE Q02156 2/20 0.31
PRKCZ Q05513 2/20 0.31
PRKCD Q05655 2/20 0.31
CAMK2B Q13554 2/20 0.31
CAMK2G Q13555 2/20 0.31
CAMK2D Q13557 2/20 0.31
CAMK2A Q9UQM7 2/20 0.31
KDM4E B2RXH2 2/20 0.31
HSD17B10 Q99714 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27199321 0.93 ALDH1A1 (0.36) DHODHALDH1A1GRM1KDM4EHSD17B10
Trifluoroacetic Acid SCHEMBL27199538 0.89 DPP4 (0.33) DHODHALDH1A1KDM4EHSD17B10MAPK1
SCHEMBL27199478 0.85 HTR3A (0.37) HTR3A
SCHEMBL27199481 0.85 HTR3A (0.37) HTR3A
SCHEMBL30498161 0.85 HTR3A (0.37) HTR3A
SCHEMBL25670293 0.79 BRD4 (0.34) ALDH1A1BRD4KDM4EMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL27199525 0.77 BRD4 (0.33) BRD4MAPTCYP2C9
SCHEMBL27199323 0.75 ALDH1A1 (0.34) DHODHALDH1A1GRM1IRAK4KDM4E
Hydrochloric Acid SCHEMBL27199563 0.74 GRM2 (0.37) BRD4
SCHEMBL25670818 0.72 ALDH1A1 (0.33) ALDH1A1KDM4ETSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 DHODH 4250/4885ALDH1A1 4805/4885GRM1 2132/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 DHODH 4250/4885ALDH1A1 4805/4885GRM1 2132/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 DHODH 4250/4885ALDH1A1 4805/4885GRM1 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.